Abstract
Background Staffing shortages and inadequate healthcare access have driven the development of artificial intelligence (AI)-enabled tools in medicine. Accuracy of these algorithms has been extensively investigated, but research on downstream effects of AI integration into the clinical workflow is lacking.
Objective We aim to analyze how integration of a basal cell carcinoma detection and tumor mapping algorithm in a Mohs micrographic surgery (MMS) unit may impact waiting times in the surgical pathology laboratory and on the floor.
Methods Time spent on each task and slide, staff, and histotechnician waiting times were analyzed over a 20 day period in a MMS unit. A simulated AI workflow was created and the time differences between the real and simulated workflows were compared.
Results Simulated addition of the algorithm led to improvements of 64% in slide waiting time (1:03:39 per case), 36% in staff waiting time (59:09 per case), and 25% in histotechnician waiting time (25:27 per case).
Limitations A single MMS unit was analyzed and AI integration was performed retrospectively, rather than in real time.
Conclusions AI integration results in significantly reduced slide, staff, and histotechnician waiting time, which enables increased productivity and a streamlined clinical workflow.
Capsule summary
The accuracy of artificial intelligence algorithms has been well established. This study addresses the impact of implementation of such an algorithm into a real-world clinical workflow.
Results indicate the potential for increased efficiency and productivity with use of artificial intelligence in Mohs micrographic surgery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JL is supported by NIH grants R24GM141194, P20GM104416 and P20GM130454.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Protection Program of Dartmouth Health gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding sources: JL is supported by NIH grants R24GM141194, P20GM104416 and P20GM130454.
Conflicts of Interest: None declared.
IRB approval status: N/A
Clinicaltrials.gov (or equivalent) listing (if applicable): N/A
Patient Consent on File: N/A
Reprint requests: Matthew LeBoeuf
Data Availability
Due to data privacy restrictions, subsets of the data produced in the present study may be made available upon reasonable request to the authors.
